Als Therapy Development Institute

Steven N Perrin

Alan Gill

Fernando G Vieira

John Monteith Lincecum

Cynthia A Gill

Bingbing Jiang

Matvey Lukashev

Kyle Denton

Theo Hatzipetros

Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.

Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders

Methods and therapeutic compositions are disclosed for treating neurological disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease and/or Huntington's disease, using Salubrinal analogs, or pharmaceutically acceptable salts, hydrates, or solvates thereof.

Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions

The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).

Copper complexes for treatment of neurodegenerative disorders

Anti-CD40L antibodies

Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies

Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia.

Method for the treatment of neurodegenerative diseases

Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis

Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that sequester, neutralize or deplete the CD8+ cytotoxic T cells.

Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases

Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.

Growing community of inventors

Newbury, MA, United States of America

Steven N Perrin